

IPR and Innovation

1. [Will India support a small firm's bid to make a cheap diabetes drug or cave in to big pharma?](#) - Scroll.in
2. [Planned IP regime to boost 'Make in India'](#) - Financial Express
3. [DIPP outlines steps to improve IPR regime](#)- Financial Chronicle

Access to Healthcare

1. [Poor prognosis](#) - Financial Express
- 1.

Others

1. [Gulf region can become top export destination for Indian pharma exporters: Dr Vinay Deshmukh](#) - Pharmabiz
2. [Future ready pharma plants](#) - Business World

IPR and Innovation

1. [Will India support a small firm's bid to make a cheap diabetes drug or cave in to big pharma?](#) – Scroll.in
A little known pharmaceutical company of Hyderabad has again lit the fuse to the volatile issue of access to medicines and patent rights in India. Lee Pharma has applied for a compulsory licence to produce a cheaper version of a patented medicine to treat diabetes, a move that is likely to set off a furious global debate on the contested aspects of India's patent law. A patent gives a company that has developed a new drug the sole right to manufacture and sell it. The monopoly normally lasts for 20 years. An international agreement called TRIPS is administered by the World Trade Organisation to ensure patents are enforced across member-countries. But there are flexibilities that allow governments to override patents to meet public health requirements, primarily through a compulsory licence. This licence is issued without the patent owner's consent to allow another company to manufacture a less-expensive generic version. However, a royalty rate is paid to the innovator company.
2. [Planned IP regime to boost 'Make in India'](#) – Financial Express
The government on Monday said it has formulated a multi-pronged strategy to develop an intellectual property (IP) regime in the country to promote creativity and give a fillip to its 'Make in India' initiative. This includes introducing a 10% rebate on online filing of applications and documents, allowing e-filers the facility of using debit cards, credit cards and internet banking as well as giving a 50% concession in fees for MSMEs to encourage them to innovate and seek protection for their inventions (MSMEs account for 45% of total industrial production and 38% of India's GDP).
3. [DIPP outlines steps to improve IPR regime](#) – Financial Chronicle
THE government on Monday said it has taken several steps to increase efficiency in processing of intellectual property applications, bring transparency and dissemination of information to improve the IPR regime. The department of industrial policy and planning (DIPP), under the commerce and industry ministry, said it has taken measures such as creation of additional posts

to reduce manpower shortage and providing fee concession for MSMEs to encourage them to innovate. “Several measures have been taken to ensure continuous and unending improvement of the Indian IP ecosystem in the country.

Access to Healthcare

1. [Poor prognosis](#) – Financial Express

A price cap on medical devices, which include stents and cardiac implants, is a very bad idea, one that the government should drop right away. Given India imports nearly 75% of its requirement of medical devices, the prices do often become a barrier for patients from the lower income group. But, given the costs of treatment at public healthcare facilities is a fourth of that at private ones, as per data from the National Sample Survey Office (NSSO), it is not as if the choices for low-income patients are very limited.

Others

1. [Gulf region can become top export destination for Indian pharma exporters: Dr Vinay Deshmukh](#) - Pharmabiz

Medicine markets in the gulf countries have huge potential for Indian drugs and the region can become the top export destination for Indian pharma exporters, according to Dr. Vinay Deshmukh, director, Regulatory and International Affairs, Sarkone Lifesciences, Ras Al Khaimah, UAE. There is considerable potential to expand shipments of medicines from India. Those who want to export their products from India can find new export markets in the UAE as majority of the population in the United Arab Emirates has a liking for Indian made medicines. UAE can become a top buyer of Indian generic or off-patent medicines, he added. He was speaking to Pharmabiz while attending the buyer-seller meeting organised by Pharmexcil at the Pharmac South trade expo in Chennai.

2. [Future ready pharma plants](#) – Business World

The challenge for the Pharma industry in adopting manufacturing excellence whilst keeping up with regulatory compliance is to design new operational procedures that comply with all external regulatory requirements, but at the same time support continuous improvement. Excellence is a gradual journey and companies have to stay committed and overcome all these initial impediments. A well-articulated excellence vision is the starting point. Control and monitoring of storage and production environments has also become an important issue within the Pharmaceutical Industry.